Recent Finacing
Recent Raise
NeoTX develops anticancer immunotherapies via its Selective T cell Redirection (STR) platform that attaches engineered bacterial determinants to tumors and activates immune cells; lead Nap in Phase 1b.
Focus Areas
Total Raised
Funding round
See the team members at NeoTX Therapeutics.
